By Super Admin

Seeking Alpha / Seaking Alpha - 20 hours ago

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Announces New Data on NRX-101 Demonstrating No Damage to Intestinal and Vaginal Flora in Validated Rodent Models Compared to Standard Antibiotics: Potential Implications for Avoidance of C. Difficile infections

New data demonstrates no impact of NRX-101 on gut or vaginal flora – considered primary causes of pseudomembranous colitis due to C difficile and vaginal yeast infections NRX-101 previously demonstrated potent activity against resistant urinary pathogens and has been shown to be fully...

Seeking Alpha / Seaking Alpha - 20 hours ago

Massimo Reported 2023 Financial Results

IRVINE, Calif., April 17, 2024 /PRNewswire/ -- Massimo Group (NASDAQ: MAMO), a company coached by ATIF Holdings Limited (NASDAQ: ATIF, hereinafter referred to as "ATIF"), announces its fiscal year 2023 financial results following a $5.85 million initial public offering. Fiscal year...